stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) EBITDA
Iovance Biotherapeutics, Inc.'s EBITDA for fiscal 2025 was −$363.2M, compared with −$357.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$261.9M. Over the past ten years it has ranged from −$431.0M (fiscal 2023) to −$26.9M (fiscal 2015); the current reading is higher than 27% of that period. Iovance Biotherapeutics, Inc. ranks 542nd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$363.2M | — |
| FY2024 | −$357.5M | — |
| FY2023 | −$431.0M | — |
| FY2022 | −$377.3M | — |
| FY2021 | −$322.7M | — |
| FY2020 | −$258.9M | — |
| FY2019 | −$209.1M | — |
| FY2018 | −$128.6M | — |
| FY2017 | −$91.9M | — |
| FY2016 | −$52.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$44.0M | — |
| Mar 2026 | −$70.6M | — |
| Dec 2025 | −$62.2M | — |
| Sep 2025 | −$85.1M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $96.1M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| PBLS Parabilis Medicines, Inc. compare | −$172.4M |
| ABCL AbCellera Biologics Inc. compare | −$192.6M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| IOVA Iovance Biotherapeutics, Inc. | −$261.9M |
| IRON Disc Medicine, Inc. compare | −$273.8M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
| XENE Xenon Pharmaceuticals Inc. compare | −$439.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on IOVA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement